TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00945009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03500380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Lapatinib 1250 mg orally once daily during each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
Study: NCT00945009

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT04294914

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Pressor Test + Virtual Reality
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test + Virtual Reality
Description: The participant submerges one limb into a tank of cold (1-2 ° C), circulating water while interacting with a virtual reality environment
Study: NCT01132586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01399008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate
Description: Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300 mg as active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 300 mg as active comparator
Study: NCT02734407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assigned Intervention
Description: All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept 2.0 mg
Description: If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
Study: NCT01860625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch
Study: NCT01399008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 300 mg as active comparator
Study: NCT01860625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT03437473

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Description: Active Implantable Vagus Nerve Stimulation device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Description: Active Implantable Vagus Nerve Stimulation device.
Study: NCT01303744

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet, once a day in the morning for 12 weeks
Study: NCT01399008

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.6 mg colchicine daily as flare prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg colchicine daily as flare prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 0.6 mg colchicine daily as flare prophylaxis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03907033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
Study: NCT01999205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity promotion
Description: A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
Study: NCT01397331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
Study: NCT00128765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an integrated self-management education program
Description: disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: regular practice nurse review (monitoring controls)
Description: protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
Study: NCT03907033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
Study: NCT00945009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT01299402

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soulera Herbal Blend
Description: This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
Study: NCT02945644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: take at bedtime for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: take at bedtime for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: take at bedtime for 14 days
Study: NCT00945009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT01057017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intervention
Study: NCT03525210

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 9-valent HPV vaccine
Description: Vaccination
Study: NCT03437473

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Description: Active Implantable Vagus Nerve Stimulation device.
Study: NCT01072617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation via MagPro x100 device
Description: Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system.
Study: NCT00030225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD
Study: NCT02920515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorlin or Leuprorelin
Description: Gonadotrophin releasing hormone agonists (GnRHa)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zhibo dihuang pills
Description: Traditional Chinese Medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabu ying pills
Description: Traditional Chinese Medicine
Study: NCT00030225

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care (Control)
Study: NCT02051621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
Study: NCT00128765

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: care at initiative of the patient (usual GP care)
Description: care at initiative of the patient (usual GP care)
Study: NCT00555932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
Study: NCT02426931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the tip-flexible ureterorenoscope
Description: Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the classic flexible ureteroscope
Description: Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
Study: NCT02051621

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cavo-tricuspid-isthmus-ablation
Description: irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
Study: NCT02904863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Extra blood draw samples
Study: NCT02054286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-1
Description: Intramuscular injection of THV01-1 (week 0)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: THV01-1
Description: Intramuscular injection of THV01-1 (week 0)
Study: NCT01397331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
Study: NCT02412241

Intervention type: OTHER
Group type: OTHER
Intervention: LEF measures
Description: Patient-reported outcome measure; clinician-reported outcome measures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Technical measure
Description: Undergo standard CT scan

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Technical measure
Description: Undergo standard ultrasound
Study: NCT02628548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: 8 week cognitive training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: 8 week cognitive training program
Study: NCT03878303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0058TA
Description: 25 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo AC0058TA
Description: equivalent dose of investigational product
Study: NCT02488993

Intervention type: OTHER
Intervention: Prospective Phase Rifaximin-α 550mg
Description: Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.

Intervention type: OTHER
Intervention: Prospective Phase No Rifaximin-α 550mg
Description: Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.

Intervention type: OTHER
Intervention: Retrospective Phase
Description: Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
Study: NCT03755661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI&TXT4MSM
Description: brief in-person intervention followed by text messaging
Study: NCT03613467

Intervention type: PROCEDURE
Intervention: VATS lobectomy
Description: Patients who received lobectomy by video-assisted thoracoscopic surgery

Intervention type: PROCEDURE
Intervention: Thoracotomy lobectomy
Description: Patients who received lobectomy by thoracotomy
Study: NCT03869476

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive diagnosis score
Description: * spleen fibrosis by elastography~* plasma cytokines levels~* mutationnal landscape by NGS~* CD34 circulating cells
Study: NCT03599323

Intervention type: DRUG
Intervention: Clotrimazole 1% (Empecid L Cream, BAYB5097)
Description: Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
Study: NCT01597024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Study
Description: Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI Study
Description: We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
Study: NCT01566487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate tablets 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine fumarate
Description: Quetiapine fumarate tablets 300mg
Study: NCT03529110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Description: T-DXd is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ado-trastuzumab emtansine (T-DM1)
Description: The treatment will be in accordance with the approved label.
Study: NCT00187070

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine
Description: See Detailed Description section for details of treatment interventions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem cell transplant,
Description: See Detailed Description section for details of treatment interventions.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: See Detailed Description section for details of treatment interventions.
Study: NCT01057524

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Chest Wall Oscillation (HFCWO)
Description: Airway clearance using the high frequency chest wall oscillator device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual airway clearance
Description: Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
Study: NCT01054521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temperature-controlled RF
Description: The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar RF
Description: The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
Study: NCT02952560

Intervention type: OTHER
Intervention: Ultrasound scan
Description: Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
Study: NCT00434356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Intravenous repeating dose
Study: NCT02461316

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
Study: NCT03680872

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bidirectional Neural Bypass System
Description: These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
Study: NCT04966923

Intervention type: OTHER
Intervention: No intervention in this study
Description: Analyses of pathogenic variant TP53 and variants in genetic test

Intervention type: OTHER
Intervention: No intervention in this study
Description: Analyses of pathogenic variant TP53 and variants in genetic test
Study: NCT03755583

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Exclusive Enteral Nutrition
Description: a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.